Initial interactions with the FDA on developing a validation dataset as a medical device development tool
出版年份 2023 全文链接
标题
Initial interactions with the FDA on developing a validation dataset as a medical device development tool
作者
关键词
-
出版物
JOURNAL OF PATHOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-06
DOI
10.1002/path.6208
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer
- (2022) Sherene Loi et al. npj Breast Cancer
- Development of Training Materials for Pathologists to Provide Machine Learning Validation Data of Tumor-Infiltrating Lymphocytes in Breast Cancer
- (2022) Victor Garcia et al. Cancers
- Pilot study to evaluate tools to collect pathologist annotations for validating machine learning algorithms
- (2022) Katherine Elfer et al. Journal of Medical Imaging
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment
- (2019) Marija Balic et al. Breast Care
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Relationship between the Ki67 index and its area based approximation in breast cancer
- (2018) Muhammad Khalid Khan Niazi et al. BMC CANCER
- Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study
- (2017) Stephen J Luen et al. LANCET ONCOLOGY
- Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
- (2016) Rico D. Bense et al. JNCI-Journal of the National Cancer Institute
- Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
- (2016) H. Raza Ali et al. PLOS MEDICINE
- Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
- (2016) Rico D. Bense et al. JNCI-Journal of the National Cancer Institute
- Immunological Mechanisms Underneath the Efficacy of Cancer Therapy
- (2016) L. Galluzzi et al. Cancer Immunology Research
- Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
- (2015) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
- (2014) Nadia Howlader et al. JNCI-Journal of the National Cancer Institute
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
- (2013) Yasmin Issa-Nummer et al. PLoS One
- Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer
- (2011) Makiko Ono et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
- (2008) C. Desmedt et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started